DK1143967T3 - Anticonvulsive derivater egnede til behandling af Hortons hovedpine - Google Patents

Anticonvulsive derivater egnede til behandling af Hortons hovedpine

Info

Publication number
DK1143967T3
DK1143967T3 DK00905615T DK00905615T DK1143967T3 DK 1143967 T3 DK1143967 T3 DK 1143967T3 DK 00905615 T DK00905615 T DK 00905615T DK 00905615 T DK00905615 T DK 00905615T DK 1143967 T3 DK1143967 T3 DK 1143967T3
Authority
DK
Denmark
Prior art keywords
horton
headache
treatment
derivatives suitable
anticonvulsant derivatives
Prior art date
Application number
DK00905615T
Other languages
Danish (da)
English (en)
Inventor
Enrique Carrazana
Steve D Wheeler
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of DK1143967T3 publication Critical patent/DK1143967T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK00905615T 1999-01-19 2000-01-13 Anticonvulsive derivater egnede til behandling af Hortons hovedpine DK1143967T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11638899P 1999-01-19 1999-01-19
PCT/US2000/000919 WO2000042996A2 (en) 1999-01-19 2000-01-13 Use of anticonvulsant derivatives for treating cluster headaches

Publications (1)

Publication Number Publication Date
DK1143967T3 true DK1143967T3 (da) 2005-01-10

Family

ID=22366884

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00905615T DK1143967T3 (da) 1999-01-19 2000-01-13 Anticonvulsive derivater egnede til behandling af Hortons hovedpine

Country Status (24)

Country Link
US (1) US6319903B1 (es)
EP (1) EP1143967B1 (es)
JP (1) JP2002535270A (es)
KR (1) KR100653326B1 (es)
CN (1) CN1182845C (es)
AT (1) ATE279921T1 (es)
AU (1) AU771388B2 (es)
BR (1) BR0008176A (es)
CA (1) CA2359541C (es)
CZ (1) CZ20012620A3 (es)
DE (1) DE60015070T2 (es)
DK (1) DK1143967T3 (es)
ES (1) ES2228465T3 (es)
HU (1) HUP0105154A3 (es)
IL (2) IL144406A0 (es)
MX (1) MXPA01007350A (es)
MY (1) MY121486A (es)
NO (1) NO20013554D0 (es)
NZ (1) NZ513115A (es)
PT (1) PT1143967E (es)
TR (1) TR200102711T2 (es)
TW (1) TWI248360B (es)
WO (1) WO2000042996A2 (es)
ZA (1) ZA200106786B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
HUP0401867A2 (hu) * 2000-08-17 2004-12-28 Teva Pharmaceutical Industries Ltd. A valproinsav-amid és a 2-valproénsav-amid származékainak használata a fájdalommal és a fejfájással járó betegségek kezelésére vagy megelőzésére
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
PL372393A1 (en) * 2002-02-26 2005-07-25 Ortho-Mcneil Pharmaceutical Inc. Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and antimigraine agents
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20070021356A1 (en) * 2002-03-18 2007-01-25 Cady Roger K Preemptive prophlyaxis of migraine
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2489984A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20040176463A1 (en) * 2003-02-05 2004-09-09 Daniella Licht Immediate release formulation of n-(2-propylpentanoyl)glycinamide
WO2004071421A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
ES2310366T3 (es) * 2004-08-24 2009-01-01 Janssen Pharmaceutica Nv Nuevos derivados de heteroaril sulfonamida benzo-condensada utiles como agentes anticonvulsivos.
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
US20110117070A1 (en) * 2005-04-19 2011-05-19 Aurora Sheena K Compositions and methods for treating headache
CA2609185A1 (en) 2005-05-20 2006-11-30 Ahmed F. Abdel-Magid Process for preparation of sulfamide derivatives
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
TW200812573A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
ES2312308T3 (es) 2006-11-17 2013-03-26 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
EP2363113B1 (en) * 2006-12-04 2017-08-02 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
US9457008B2 (en) 2012-03-23 2016-10-04 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Joint product comprising synephrine and topiramate
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US20220016074A1 (en) 2018-11-21 2022-01-20 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
DK0932400T3 (da) * 1996-10-08 2003-02-10 Ortho Mcneil Pharm Inc Antikonvulsive derivater, der er nyttige ved behandling af neuropatisk smerte

Also Published As

Publication number Publication date
CA2359541A1 (en) 2000-07-27
TR200102711T2 (tr) 2001-12-21
ATE279921T1 (de) 2004-11-15
KR100653326B1 (ko) 2006-12-04
TWI248360B (en) 2006-02-01
HUP0105154A3 (en) 2004-10-28
CA2359541C (en) 2005-06-21
WO2000042996A2 (en) 2000-07-27
EP1143967B1 (en) 2004-10-20
CN1352555A (zh) 2002-06-05
IL144406A (en) 2006-08-20
AU2726800A (en) 2000-08-07
WO2000042996A3 (en) 2000-12-07
JP2002535270A (ja) 2002-10-22
US6319903B1 (en) 2001-11-20
KR20010101595A (ko) 2001-11-14
NO20013554L (no) 2001-07-18
IL144406A0 (en) 2002-05-23
CN1182845C (zh) 2005-01-05
CZ20012620A3 (cs) 2002-09-11
MXPA01007350A (es) 2003-06-06
MY121486A (en) 2006-01-28
DE60015070T2 (de) 2006-01-05
AU771388B2 (en) 2004-03-18
PT1143967E (pt) 2005-01-31
EP1143967A2 (en) 2001-10-17
ES2228465T3 (es) 2005-04-16
BR0008176A (pt) 2001-11-06
HUP0105154A2 (hu) 2002-04-29
DE60015070D1 (de) 2004-11-25
NO20013554D0 (no) 2001-07-18
ZA200106786B (en) 2002-11-18
NZ513115A (en) 2004-11-26

Similar Documents

Publication Publication Date Title
DK1143967T3 (da) Anticonvulsive derivater egnede til behandling af Hortons hovedpine
ATE304358T1 (de) (s,s)-reboxetin zur behandlung von migränekopfschmerzen
BR9710993A (pt) Derivados anticonvulsivos úteis no tratamento de esclerose lateral amiotrófica (als)
BR9710994A (pt) Derivados anticonvulsivos úteis no tratamento de obesidade.
DE60010098D1 (de) 28-epirapaloge
BR0010220A (pt) Compostos de pirimidinona
MA26782A1 (fr) Pyrazolobenzodiazepines en tant qu'inhibiteurs de cdk2.
BR9609631A (pt) Isocromanos 1,6-dissubstituídos para tratamento de cefaléias de enxaqueca
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
DK1143917T3 (da) Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
BR0013092B1 (pt) espessante/clarificador e processo para operar o espessante/clarificador.
BR9914722A (pt) Derivados de anticonvulsivo úteis no tratamento de dependência, vìcio e abuso do álcool
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
BR9710992A (pt) Derivados anticovulsivos úteis no tratamento de psorìase
DK1459751T3 (da) (S,S)reboxetin til behandling af migrænehovedpine
BR9909878A (pt) 10-canfosulfonato de paroxetina para tratamento de distúrbios do sistema nervoso central
IT1317829B1 (it) Processo per la preparazione di cefonicid per via enzimatica.
ITMI940516A0 (it) Macchina discontinua per il trattamento ad umido in largo di tessuti in genere
IT1294583B1 (it) Procedimento di formatura di capsuloni per bottiglie e macchina per attuare il procedimento.
ITBO970720A0 (it) Procedimento per il trattamento di tessuti.
IT1313588B1 (it) Processo per la preparazione di trans-4-p-fluorofenil-3-idrossimetil-piperidina.
IT1307824B1 (it) Processo per la preparazione di lidocaina.
UA3391S (uk) Набір етикеток для вина "таємниця херсонесу"
IT1280629B1 (it) Tripeptide per il trattamento delle forme cancerose, in particolare per il trattamento del melanoma.
IT1285146B1 (it) Procedimento per la realizzazione di configurazioni di polisilicio drogato in transistori mos.